The Promise of Upskilling in Manufacturing

On this episode of the Voices of eLearning, HP Director of EdTech Innovation Mike Belcher joined host JW Marshall to explore how HP is navigating the intersection of education and technology and helping elevate education from K-12 all the way through professional education.

Like everyone in the industry, Belcher said the COVID-19 pandemic has had an enormous impact on the state of education and the technology that powers it.

“There are some market dynamics that don’t make sense to us, yet,” he said. “I think everyone was feeling pretty decent [before COVID]. … When COVID hit and everyone quarantined and went home, whether that was from school or work or whatever, I think, honestly, people have handled this far better, in many cases, than I expected.”

Still, there was a particular area that caught Belcher and others in the industry slightly off guard – “how at-risk many of our businesses were.” In particular, he cited retail, hospitality and travel as industries that have struggled to keep pace with the shifting environment.

However, other industries, such as additive manufacturing, are showing great promise and an elevated willingness to engage in the types of forward-looking planning and execution that will drive results.

Those results will be dependent on continuing education, including the reskilling and upskilling of the workforce that will facilitate all that growth.

“I think things will kind of morph. First off, your low-skill, repetitive manufacturing jobs – those are going to be a thing of the past, and we have to think that way and be smart enough not to try and regenerate jobs that don’t have a future,” Belcher said. “What I think this allows us to do is scale printing or manufacturing in small-scale levels, but it requires far more skill.”

Stay Tuned for a New Episode Thursday!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More